Drug intelligence / Profile preview

DNP002

Development stage: Phase 1
Lead developer: KumhoHT
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DNP002 is a humanized monoclonal antibody targeting the carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6). It is primarily developed for the treatment of solid tumors. The drug works by inducing antibody-dependent cell cytotoxicity (ADCC) and has shown potential in depleting cancer cells and myeloid-derived suppressor cells (MDSC). It is administered intravenously.

Other names: DNP-002DNP002DNP 002

Targets

CEACAM6

Beyond the preview

Go deeper on DNP002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNP002.

Explore the full profile